Antibody-drug conjugates in oncology: insights into Current challenges
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antibody-drug conjugates in oncology: insights into Current challenges
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume -, Issue -, Pages 1-4
Publisher
Informa UK Limited
Online
2023-10-27
DOI
10.1080/14712598.2023.2276288
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
- (2023) Toan D. Nguyen et al. Cancers
- Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study.
- (2023) Rachel Occhiogrosso Abelman et al. JOURNAL OF CLINICAL ONCOLOGY
- Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
- (2023) Andrea D’Arienzo et al. EClinicalMedicine
- MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy
- (2022) Aysooda Hosseinzadeh et al. Cancer Cell International
- Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
- (2022) Eleonora Nicolò et al. CANCER TREATMENT REVIEWS
- Potential of antibody–drug conjugates (ADCs) for cancer therapy
- (2022) Hany E. Marei et al. Cancer Cell International
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
- (2022) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-targeted delivery of a STING agonist improvescancer immunotherapy
- (2022) You-tong Wu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Unlocking the potential of antibody–drug conjugates for cancer therapy
- (2021) Joshua Z. Drago et al. Nature Reviews Clinical Oncology
- The Chemistry Behind ADCs
- (2021) Vesela Kostova et al. Pharmaceuticals
- Trastuzumab deruxtecan for HER2+ advanced breast cancer
- (2021) Jiyun Lee et al. Future Oncology
- Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer
- (2020) Angeliki Andrikopoulou et al. Clinical Breast Cancer
- An overview of process development for antibody-drug conjugates produced by chemical conjugation technology
- (2020) Yutaka Matsuda et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
- (2019) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody–drug conjugates for cancer
- (2019) Cindy H Chau et al. LANCET
- DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance
- (2017) Naoki Takegawa et al. INTERNATIONAL JOURNAL OF CANCER
- An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression
- (2017) Luis J Schwarz et al. JNCI-Journal of the National Cancer Institute
- An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression
- (2017) Luis J Schwarz et al. JNCI-Journal of the National Cancer Institute
- A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
- (2016) John Y. Li et al. CANCER CELL
- Antibody-drug conjugates as novel anti-cancer chemotherapeutics
- (2015) C. Peters et al. BIOSCIENCE REPORTS
- Evolving Strategies for Target Selection for Antibody-Drug Conjugates
- (2015) Marc Damelin et al. PHARMACEUTICAL RESEARCH
- Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy
- (2014) Ravi V. J. Chari et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started